Efficacy and Safety of Sequential IV/PO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin, in the Treatment of Patients With Community-acquired Pneumonia

Inclusion Criteria: * Patients aged 18 years or above * All of the following signs and symptoms of pneumonia: * Fever (core/ rectal/ tympanic temperature \>/= 38.5°C or axillary/ oral/ cutaneous temperature \>/= 38.0°C) or hypothermia (core/ rectal/ tympanic temperature \</= 35.5°C or axillary/ oral/ cutaneous temperature \</= 35.0°C) * White blood cell (WBC) count \> 10,000/µL, or \>/= 15% immature neutrophils (bands), regardless of the peripheral WBC count, or total WBC count \< 4,500/µL * The presence of at least 2 of the following symptoms: - Cough- Purulent sputum production * Dyspnoea or tachypnoea (respiratory rate \> 20 breaths/minute) * Rigors and/or chills- Chest pain * Auscultatory findings on pulmonary examination of rales/crackles and/or evidence of pulmonary consolidationAND * Radiological evidence of (an) infiltrate(s) consistent with bacterial pneumonia at baseline or within 24 hours following enrolment * Fine score \>/= 71 (i.e. Pneumonia PSI risk Class III, IV or V, requiring hospitalisation for the treatment of CAP) * Written informed consent obtained from the patient or a next-of-kin Exclusion Criteria: * Known hypersensitivity to fluoroquinolones, or other quinolones, and/or to beta-lactams, or any of the excipients * Female patients who are pregnant or lactating * History of tendon disease/disorder related to quinolone treatment * Known congenital or documented-acquired QT prolongation; concomitant use of drugs, reported to increase the QT interval; uncorrected hypokalaemia; clinically relevant bradycardia; clinically relevant heart failure with reduced left * ventricular ejection fraction; previous history of symptomatic arrhythmias * History of epilepsy- Known glucose-6-phosphate dehydrogenase deficiency * Known severe impaired liver function (i.e. Child Pugh C), (refer to Section 10.4 for definition) or transaminases increase \> 5 fold ULN- Hospitalisation for \> 48 hours before developing pneumonia, or discharge from hospital \< 30 days prior- Systemic antibacterial therapy for more than 24 hours within 14 days of enrolment * Patients requiring concomitant systemic antibacterial agents * Known structural lung disease (e.g. cystic fibrosis, bronchiectasis, or lung cancer), or other known conditions (e.g. malnutrition) predisposing to infection with nosocomial-like organisms such as Pseudomonas aeruginosa * Lung abscess, pleural empyema, risk factors for aspiration pneumonia (e.g. recent stroke, head injury, dementia) * Known rapidly fatal underlying disease (death expected within 6 months) * Known or suspected active tuberculosis or endemic fungal infection- Neutropenia (neutrophil count \< 1,000/µL) caused by immunosuppressive therapy or malignancy * Patients known to have AIDS (CD4 count \< 200/µL) or HIV-seropositive patients receiving HAART * Previous enrolment in this study * Participation in any clinical investigational drug study within the previous 4 weeks * Patient with pre-terminal renal failure (creatinine clearance \< 10 mL/min) and patients undergoing haemodialysis